patients with cancer by outlining all imaging procedures recommended in the NCCN Guidelines, including radiographs, CT scans, MRI, functional nuclear medicine imaging (PET, SPECT), and ultrasound. NCCN is recognized by Centers for Medicare & Medicaid
Search Results
-weighted MRI for analysis of in vivo tumor cellularity. Patients are followed up for 5 years after completion of study therapy. Primary Outcome Measures: Determine maximum tolerated dose of vorinostat given in combination with capecitabine and RT
expression and genome-wide copy number using gene, microRNA, and CGH arrays Assess the use of dynamic contrast-enhanced MRI in STS evaluation. Contacts: William Tap, MD • 212-639-5720 Gary Schwartz, MD • 212-639-8324 ClinicalTrials
extraction on drug bioavailability. Secondary Objectives: Assess by RECIST clinical responses signals in a broad array of solid tumors. Evaluate whether dynamic contrast enhanced MRI to determine the degree of vascular permeability and PET scan to
Robert Torrey, Philippe E. Spiess, Sumanta K. Pal, and David Josephson
imaging modality for diagnosing RCC and evaluating the extent and stage of disease. MDCT has been associated with 91% accuracy for tumor staging and up to 100% accuracy for assessment of venous tumor invasion. 2 With improvements in CT technology, MRI
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Sam Bhayani, William P. Bro, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Mayer Fishman, Thomas H. Gallagher, John L. Gore, Steven L. Hancock, Michael R. Harrison, Won Kim, Christos Kyriakopoulos, Chad LaGrange, Elaine T. Lam, Clayton Lau, M. Dror Michaelson, Thomas Olencki, Phillip M. Pierorazio, Elizabeth R. Plimack, Bruce G. Redman, Brian Shuch, Brad Somer, Guru Sonpavde, Jeffrey Sosman, Mary Dwyer, and Rashmi Kumar
CT is more accurate than chest radiograph for chest staging. 21 – 23 Abdominal MRI is used to evaluate the inferior vena cava if tumor involvement is suspected, or it can be used instead of CT for detecting renal masses and for staging when contrast
David G. Pfister, Sharon Spencer, David Adelstein, Douglas Adkins, Yoshimi Anzai, David M. Brizel, Justine Y. Bruce, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, David W. Eisele, Moon Fenton, Robert L. Foote, Thomas Galloway, Maura L. Gillison, Robert I. Haddad, Wesley L. Hicks Jr., Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Ellie Maghami, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, James W. Rocco, Cristina P. Rodriguez, Jatin P. Shah, Randal S. Weber, Gregory Weinstein, Matthew Witek, Frank Worden, Sue S. Yom, Weining Zhen, Jennifer L. Burns, and Susan D. Darlow
. Initial imaging of the primary site is done with CT and/or MRI. MRI is generally preferred over CT in patients with cranial nerve symptoms or to evaluate cranial nerve involvement or tumors that encroach on the skull base. CT, conversely, is complementary
Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak
resonance imaging (MRI). Future imaging options include multislice CT scanners and positron emission tomography (PET)-CT fusion studies, which may be particularly helpful in distinguishing compression fractures from pathologic fractures. Biomarkers in Bone
Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Lucille A. Leong, Edward Lin, Michael G. Martin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Deborah A. Freedman-Cass, and Kristina M. Gregory
and MRI, enables preoperative assessments of depth of tumor penetration and the presence of local lymph nodal metastases. 78 The consensus of the panel is that a PET scan is not routinely indicated. Additional information regarding the extent of
Ronald S. Go, Eric Jacobsen, Robert Baiocchi, Ilia Buhtoiarov, Erin B. Butler, Patrick K. Campbell, Don W. Coulter, Eli Diamond, Aron Flagg, Aaron M. Goodman, Gaurav Goyal, Dita Gratzinger, Paul C. Hendrie, Meghan Higman, Michael D. Hogarty, Filip Janku, Reem Karmali, David Morgan, Anne C. Raldow, Alexandra Stefanovic, Srinivas K. Tantravahi, Kelly Walkovich, Ling Zhang, Mary Anne Bergman, and Susan D. Darlow
’s LCH is single or multisystem is unknown in the absence of staging. Therefore, whole-body PET/CT should be considered for patients with suspected multisystem disease. Abnormal brain MRI is often observed in LCH, even in the absence of neurologic
